Clinical Trials on Nevi, Dysplastic in Netherlands

Total 185 results

Natasha Appelman-Dijkstra

Recruiting

DEnosumab for the Treatment of FIbrous Dysplasia/McCune-Albright Syndrome in Adults (DeFiD) (DeFiD)

Fibrous Dysplasia | McCune Albright Syndrome

Netherlands
University Medical Center Groningen

Completed

VEGF-targeted Fluorescence Near-Infrared (NIR) Endoscopy in (Pre)Malignant Esophageal Lesions (VICE)

Esophageal Cancer | Dysplasia

Netherlands
Catharina Ziekenhuis Eindhoven
Tilburg University

Completed

EBIS: The Eindhoven Breech Intervention Study

Stress, Psychological | Congenital Hip Dysplasia | Breech Presentation | Thyroid Hormones | External Cephalic Version

Netherlands
Radboud University Medical Center

Completed

myDC/pDC in Stage III Melanoma Patients

Melanoma

Netherlands
Radboud University Medical Center

Completed

Natural Dendritic Cell Vaccines in Metastatic Melanoma Patients

Melanoma

Netherlands
Institut National de la Santé Et de la Recherche...
Charite University, Berlin, Germany; Cliniques universitaires Saint-Luc- Université... and other collaborators

Completed

Effect of Risedronate on Bone Morbidity in Fibrous Dysplasia of Bone (PROFIDYS)

Fibrous Dysplasia of Bone

Belgium, France, Germany, Netherlands
University Medical Center Groningen

Not yet recruiting

Oral Bevacizumab-800CW and Cetuximab-800CW Administration to Detect Early Esophageal Adenocarcinomas (SLURP)

Esophageal Adenocarcinoma | Barrett's Esophagus Without Dysplasia | Barrett Oesophagitis With Dysplasia

Netherlands
A.J.M. van den Eertwegh
Idera Pharmaceuticals, Inc.

Recruiting

A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma (INTRIM)

Malignant Melanoma

Netherlands
Foundation for Liver Research
Interscope, Inc.

Completed

EndoRotor® Ablation of Barrett's Esophagus: Safety and Feasibility Study

Barretts Esophagus With Dysplasia

Netherlands
The Netherlands Cancer Institute
4SC

Active, not recruiting

Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma (DONIMI)

Malignant Melanoma Stage III

Netherlands
Zuyderland Medisch Centrum

Recruiting

Exploring an Alternative Pre-operative SLN Mapping Method Using a Magnetic Tracer and MRI for Melanoma Patients (SCARLETT)

Melanoma

Netherlands
Zuyderland Medisch Centrum

Completed

Sentinel Lymph Node Mapping Using Magtrace and MRI in Healthy Subjects for Potential Use in Melanoma Patients (TRACIE)

Melanoma

Netherlands
Radboud University Medical Center

Completed

Single-step Antigen Loading and TLR Activation of Dendritic Cells in Melanoma Patients

Melanoma

Netherlands
NinePoint Medical

Completed

A Comparison of Volumetric Laser Endomicroscopy (VLE) and Endoscopic Mucosal Resection (EMR) in Patients With Barrett's Dysplasia or Intramucosal Adenocarcinoma

Intramucosal Adenocarcinoma | Barrett'S-associated Dysplasia

Netherlands
University Medical Center Groningen

Completed

Molecular Fluorescence Endoscopy of (Pre)Malignant Esophageal Lesions (EAGLE)

Esophageal Cancer | Barrett Esophagus | Dysplasia in Barrett Esophagus

Netherlands
Radboud University Medical Center

Completed

Toll-like Receptor (TLR) Ligand Matured Dendritic Cell Vaccination in Melanoma Patients

Melanoma

Netherlands
Radboud University Medical Center

Completed

Platin-based Chemotherapeutics to Enhance Dendritic Cell Vaccine Efficacy in Melanoma Patients

Melanoma

Netherlands
The Netherlands Cancer Institute
Merck Sharp & Dohme LLC

Unknown

Study Comparing Pembrolizumab With Dual MAPK Pathway Inhibition Plus Pembrolizumab in Melanoma Patients (IMPemBra)

Metastatic Melanoma

Netherlands
The Netherlands Cancer Institute

Recruiting

FMT to Convert Response to Immunotherapy

Melanoma Stage IV | Melanoma Stage III

Netherlands
Bristol-Myers Squibb

Completed

Long Term Quality of Life in Melanoma Patients in Netherlands

Melanoma

Netherlands
The Netherlands Cancer Institute
University of Pavia; Academisch Medisch Centrum - Universiteit van Amsterdam... and other collaborators

Recruiting

'Cancer Patients Better Life Experience' (CAPABLE)

Melanoma

Netherlands
Amsterdam UMC, location VUmc
Bristol-Myers Squibb

Recruiting

Uptake and Biodistribution of 89Zirconium-labeled Ipilimumab in Ipilimumab Treated Patients With Metastatic Melanoma (Zirconipi)

Melanoma

Netherlands
University of Twente

Not yet recruiting

MR Lymphography and Magnetic Sentinel Lymph Node Biopsy in Melanoma Patients (MelaDiff)

Melanoma (Skin)

Netherlands
Leiden University Medical Center

Recruiting

SGM-101 Tumor Targeted Fluorescence Endoscopy in Rectal Polyps With Suspected T1 Adenocarcinoma or High Grade Dysplasia (SGM-T1)

Colorectal Cancer | Image | Low Grade Dysplasia of Colon

Netherlands
The Netherlands Cancer Institute
Bristol-Myers Squibb

Active, not recruiting

Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients (OpACIN)

Stage III Skin Melanoma

Netherlands
The Netherlands Cancer Institute
Amgen

Active, not recruiting

Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (Stage IIIB/C/D-IV M1a) Melanoma With Injectable Disease (NIVEC)

Melanoma Stage IV | Melanoma Stage III

Netherlands
Maastricht University Medical Center

Withdrawn

Diagnostics for the Treatment of Progressive Mucosal Lesions of the Oral Cavity: a Prospective Study

Chromosomal Instability | Low Grade Dysplasia Oral Cavity | Loss of Heterozygostiy | Fluorescence In Situ Hybridization

Netherlands
The Netherlands Cancer Institute

Unknown

Study With T-cel Receptor Gene Therapy in Metastatic Melanoma (TCR)

Stage IV Skin Melanoma | Eye; Melanoma

Netherlands
University Medical Center Groningen

Unknown

Comparing Follow-Up Schedules in Patients With Newly Diagnosed Stage IB or Stage II Melanoma

Melanoma (Skin)

Netherlands
University Medical Center Groningen

Completed

Elevated LDH Serum Levels and FDG-PET in Metastatic Melanoma Patients

Melanoma

Netherlands
The Netherlands Cancer Institute

Unknown

HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma

Melanoma | Skin Neoplasms

Netherlands
The Netherlands Cancer Institute
Copenhagen University Hospital at Herlev

Active, not recruiting

Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma (TIL)

Metastatic Melanoma

Netherlands, Denmark
The Netherlands Cancer Institute

Not yet recruiting

Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma (MARIANE)

Melanoma

Netherlands
University Medical Center Groningen

Terminated

IL2 Imaging in Metastatic Melanoma

Melanoma

Netherlands
Radboud University Medical Center
ZonMw: The Netherlands Organisation for Health Research and Development; Dutch...

Active, not recruiting

Melanoma Patients Immunized With Natural DenDritic Cells (MIND-DC)

Melanoma (Skin)

Netherlands
Erasmus Medical Center
Ludwig Institute for Cancer Research; Dutch Cancer Society; Stichting Coolsingel... and other collaborators

Recruiting

MAGE-C2 TCR T Cell Trial to Treat Melanoma and Head and Neck Cancer (MC2TCR)

Melanoma | Head and Neck Cancer | Melanoma, Uveal

Netherlands
University Medical Center Groningen

Completed

Retrospective Analysis of Response Markers and Adverse Events in Melanoma Patients Treated With Pembrolizumab

Melanoma

Netherlands
Erasmus Medical Center

Recruiting

Nivolumab Dose Optimization in Patients With a Complete, Partial or Stable Response (NIVOPTIMIZE)

Melanoma

Netherlands
Radboud University Medical Center
Dutch Cancer Society

Completed

Dendritic Cell Vaccination in Melanoma Patients Scheduled for Regional Lymph Node Dissection

Melanoma Stage III or IV

Netherlands
University Medical Center Groningen

Completed

PD-L1 PET Imaging in Melanoma Patients

Melanoma

Netherlands
Radboud University Medical Center
Dutch Cancer Society

Completed

Peptide-pulsed vs. RNA-transfected Dendritic Cell Vaccines in Melanoma Patients

Melanoma Stage III or IV

Netherlands
Leiden University Medical Center

Recruiting

Prospective Registration Of Patient Data and Quality of Life in Eye Melanoma Patients (PROQEM)

Uveal Melanoma

Netherlands
Erasmus Medical Center

Recruiting

Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial

Immunotherapy | Melanoma Stage IV | Melanoma Stage III | Toxicity, Drug

Netherlands
Leiden University
Bristol-Myers Squibb

Active, not recruiting

TIL and Anti-PD1 in Metastatic Melanoma (ACTME)

Effects of Immunotherapy | Adverse Drug Event | Toxicity, Drug

Netherlands
University Medical Center Groningen

Completed

Identification of Predictive Parameters for Colitis in Melanoma Patients Treated With Immunotherapy. (COLIPI)

Melanoma | Colitis

Netherlands
AstraZeneca

Completed

Study to Assess the Effect of Dosing AZD6244 HydSulfate in the Presence and Absence of Food in Patients With Advanced Solid Malignancies

Melanoma | Malignant Melanoma

United Kingdom, Netherlands
Netherlands Working Group on Immunotherapy of Oncology
Hoffmann-La Roche; Amsterdam UMC, location VUmc; The Netherlands Cancer Institute

Terminated

Vemurafenib Plus Cobimetinib in Metastatic Melanoma (REPOSIT)

Metastatic Melanoma

Netherlands
Leiden University Medical Center
Pierre Fabre Laboratories

Recruiting

(Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma

Melanoma Stage III | In-Transit Metastasis of Cutaneous Melanoma

Netherlands
University Medical Center Groningen

Recruiting

POINTING: Clinical Cohort Study of Patients With Melanoma and NSCLC Receiving Checkpoint Inhibitors (POINTING)

Melanoma | Non-Small Cell Lung Cancer

Netherlands
Radboud University Medical Center
Universitaire Ziekenhuizen KU Leuven

Completed

Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections (PIRAÑA)

Acute Graft Versus Host Disease | Allogeneic Stem Cell Transplant | Acute Myeloid Leucaemia | Myelo Dysplastic Syndrome

Belgium, Netherlands

Clinical Trials on Nevi, Dysplastic in Netherlands

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Togo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations